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Germ line or hypothalamus-specific deletion of Y2 receptors in
mice results in adoublingof trabecularbonevolume.However, the
specific mechanism by which deletion of Y2 receptors increases
bonemass has not yet been identified. Here we show that cultured
adherent bonemarrowstromal cells fromY2/mice alsodemon-
strate increased mineralization in vitro. Isolation of two popula-
tions of progenitor cell types, an immaturemesenchymal stem cell
population and amore highly differentiated population of progen-
itor cells, revealed a greater number of the progenitor cells within
the bone of Y2/mice. Analysis of Y receptor transcripts in cul-
tured stromal cells from wild-type mice revealed high levels of Y1
but not Y2, Y4, Y5, or y6 receptor mRNA. Interestingly, germ line
Y2 receptor deletion causes Y1 receptor down-regulation in stro-
mal cells and bone tissue possibly due to the lack of feedback inhi-
bitionofNPYrelease and subsequent overstimulationofY1 recep-
tors. Furthermore, deletion of Y1 receptors resulted in increased
bone mineral density in mice. Together, these findings indicate
that the greater number of mesenchymal progenitors and the
altered Y1 receptor expression within bone cells in the absence of
Y2 receptors are a likely mechanism for the greater bonemineral-
ization in vivo and in vitro, opening up potential new treatment
avenues for osteoporosis.
A role for the neuropeptide Y (NPY)4 receptor system in the
regulation of bone formation was first revealed with the dem-
onstration that germ line deletion of Y2 receptors resulted in
increased bone formation in the distal femur of mice. This
increase in bone formationwas due to elevated osteoblast activ-
ity and resulted in a 2-fold greater trabecular bone volume and
significantly elevated cortical bone mass compared with wild-
typemice (1, 2). Interestingly, conditional deletion of Y2 recep-
tors solely from the hypothalamus of adult mice produced a
comparable increase in bone volume within just 5 weeks, dem-
onstrating this to be a potent and centrally mediated pathway
(1, 2). However, the mechanism by which ablation of either
germ line or hypothalamic Y2 receptors stimulates osteoblast
activity to increase bone formation is not yet known.
The control of bone remodeling has been traditionally
thought to be regulated primarily by endocrine systems and by
locally acting factors such as cytokines and growth factors.
However, this view is gradually changing with increasing evi-
dence that neuronal factors are also able to modify the activity
of bone cells. The presence of nerve fibers and neuronal factors
within bone tissue has been demonstrated by a number of stud-
ies (3, 4). Furthermore, retrograde tracing studies have demon-
strated that neuronal input into bone tissue has connections to
the hypothalamus, consistent with the demonstration that con-
ditional Y2 receptor deletion in the hypothalamus is capable of
altering bone formation (1, 5).
NPY-immunoreactive fibers have been shown within bone
marrow, periosteum, and bone tissue, preferentially associated
with vascular elements, with some located around bone lining
and marrow cells (3, 6–10). The direct modulation of bone cell
activity by various neuronal factors has also been demonstrated
in vitro. Peptides such as calcitonin gene-related peptide and
substance P, aswell as calcitonin gene-related peptide receptors
and neurokinin-1 receptors are located on bone cells and have
beendemonstrated tomodify bone cell function (11–15).Other
neuropeptides in addition to NPY have also been identified
within bone tissue. For example, the presence of vasoactive
intestinal peptide receptors has been demonstrated on both
these cell types and vasoactive intestinal peptide has been
shown to regulate the activity of both osteoblasts and oste-
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oclasts (12, 16–18). Recent studies have revealed that the cen-
tral antiosteogenic action of leptin is mediated via the sympa-
thetic nervous system, whereas -adrenergic receptors have
been identified on osteoblasts and osteoblast-like cell lines
from human, rat, and mouse (19–21). The presence of neural
factors and their receptors within bone cells and their ability to
modulate bone cell activity therefore support a potential phys-
iological role for neural factors in the regulation of bone
function.
The bone-forming osteoblasts originate from mesenchymal
stem cells (MSCs), a multipotential cell type that is also able to
give rise to adipocytes and chondrocytes (22–24). The isolation
and characterization of MSCs has proven to be difficult due to
their rarity within bone, lack of knowledge of their localization
within bone, and the lack of specific markers for their identifi-
cation (25). Various methods have been utilized by different
groups to isolate a homogenous population of multipotential
mesenchymal progenitors from mice. For example, the immu-
nodepletion of hematopoietic cells following plastic adhesion
of stromal cells resulted in a population of cells that expressed
stem cell antigen-1 (Sca-1), an antigen previously associated
with hematopoietic cells, and were subsequently demonstrated
to exhibit adipogenic, chondrogenic, and osteogenic potential
(26, 27). Selection based on 5-flurouracil resistance and fluores-
cence-activated cell sorting (FACS) using wheat germ aggluti-
nin and Sca-1 was used for the identification of a candidate
osteoprogenitor cell population in mouse bone marrow (28). A
method to isolate an immature stromal progenitor cell popula-
tion from the tissue surrounding bone marrow by depletion of
hematopoietic cells followed by cell sorting to isolate Sca-1
cells was recently developed in one of our laboratories. This cell
population exhibited properties of mesenchymal stem cells,
being highly proliferative with a high capacity to form colony
forming units (CFUs) and exhibitingmultipotentiality, with the
ability to differentiate downosteoblastic, adipogenic, and chon-
drocytic lineages (25). Furthermore, additional sorting of the
Sca-1 population of cells using an antibody recognizing CD51
eliminated CD51 erythroid precursor cell types and yielded a
more mature “osteoprogenitor” cell population.
Here we have investigated whether a change in the osteo-
progenitor cell population may contribute to the greater
bone formation and bone volume of the Y2 receptor-defi-
cient models. We reasoned that a change in the release of
factors may affect the number or the ability of bone-forming
precursor cells to develop into mature mineral-producing
osteoblasts. To test this we evaluated the ability of bone mar-
row stromal cells from Y2/ mice to produce mineral in
vitro. We also assessed the number of mesenchymal and pro-
genitor cells in these mice. Furthermore, we investigated
whether Y receptors are expressed in this stromal cell pop-
ulation and whether an alteration in Y receptor expression
may also constitute a mechanism by which deletion of Y2
receptors leads to increased bone formation in vivo. The
results revealed that down-regulation of local Y1 receptor
signaling may provide a mechanism for the greater bone for-
mation of the Y2/ model.
EXPERIMENTAL PROCEDURES
Animal experiments were approved by the Garvan/St.
Vincent’s Animal Experimentation Ethics Committee and
were conducted in accordance with relevant guidelines and
regulations.
Generation of Y1/ and Y2/ Mutant Mice—Germ line
deletion of Y1 andY2 receptor genes (Npy1r andNpy2r, respec-
tively)was achieved as previously described (29, 30), by crossing
Y1 and Y2 receptor-floxed mice (Y1lox/lox and Y2lox/lox) with
oocyte-specific Cre-recombinase-expressing C57/BL6 mice
(31), resulting in the removal of the entire coding region of the
Y1 or Y2 gene.
Isolation of Bone Marrow Stromal Cells—To isolate plastic-
adherent bone marrow stromal cells, 5- to 9-week-old male
wild-type and germ line Y2/mice were sacrificed by cervical
dislocation, and marrow was flushed from femurs and tibias
with -minimal essential medium containing 10% fetal bovine
serum, 2 mM L-glutamine, 2.2g/liter sodium bicarbonate, 0.017
M HEPES, 100 IU/ml, 100 g/ml penicillin/streptomycin, and
34,000 IU/ml, 34 mg/liter gentamycin (Control media). Cells
were plated at a density of 1.9 106 cells/cm2 in 50-cm2 plastic
tissue culture plates (BD Biosciences Labware, Franklin Lakes,
NJ) andmaintained at 37 °Cwith 5% humidified CO2. The non-
adherent cell population was removed after 72 h by a medium
change. Cells were trypsinized 4 days later (0.25% trypsin con-
taining 0.53 mM EDTA) and re-plated at 6.6 104 cells/cm2 in
control media. Cells were changed into differentiation media 2
days later.
Differentiation of Bone Marrow Stromal Cell Cultures—Dif-
ferentiation into adipocytes andmineral-producing osteoblasts
was achieved by using adipogenic (control -minimal essential
mediummediawith 5g/ml insulin and 10nMdexamethasone)
or osteogenic media (control -minimal essential medium
media with 50 mg/liter ascorbic acid and 10 mM -glycerol
phosphate), respectively.
Staining of Bone Marrow Stromal Cells for Assessment of
Osteoblast and Adipocyte Differentiation—Cells were fixed in
2% paraformaldehyde for 10 min at room temperature. Osteo-
blast differentiation and mineralization of extracellular matrix
were visualized by von Kossa staining with 2% silver nitrate
under UV light for 30 min. The extent of mineralization was
assessed using the Leica QWin imaging system (Leica Micro-
systems, Heerbrugg, Switzerland). Formation of adipocytes
was visualized using Oil Red-O (12% Oil Red-O, 60% isopro-
panol). The extent of adipogenic differentiation was assessed
by counting the number of cells containing well stained oil
droplets in 10 random low power visual fields using the
QWin imaging system.
RNA Extraction and Reverse Transcription-PCR Analysis of
Cultured Bone Marrow Stromal Cells—RNAwas isolated from
cultures of bone marrow stromal cells in 12-well plates using
TRIzol reagent as per themanufacturer’s instructions. reverse
transcription-PCR was performed with TaqDNA polymerase
(Roche Applied Science) using 1 l of cDNA synthesized from
1 g of total RNA with oligo(dT)20 by using the SuperScript III
First-Strand Synthesis System for reverse transcription-PCR
(Invitrogen). The specific primers and annealing temperatures
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used along with the resultant product size obtained are as fol-
lows: mY1 receptor (323 bp, 55 °C, forward: 5-CTCGCTGG-
TTCTCATCGCTGTGGAACGG-3, reverse: 5-GCGAATG-
TATATCTTGAAGTAG-3), mY2 receptor (520 bp, 60 °C,
forward: 5-TCCTGGATTCCTCATCTGAG-3, reverse: 5-
GGTCCAGAGCAATGACTGTC-3), mY4 receptor (367 bp,
56 °C, forward: 5-TCTACAGACAGTAGACCAGG-3,
reverse: 5-GTAGGTTGGTCACATTGGAC-3), mY5 recep-
tor (204 bp, 60 °C, forward: 5-GGGCTCTATACATTTGTA-
AGTCTTCTGGG-3, reverse: 5-CATGGCTTTGCCGAAC-
ATCCACTGATCC-3), mY6 receptor (347 bp, 56 °C, forward:
5-GGAGGGATGGTTATTGTGAC-3, reverse: 5-GTTGT-
TGCTCTTGCCACTGG-3), and mouse glyceraldehyde-3-
phosphate (269 bp, 57 °C, forward: 5-ACTTTGTCAAGCTC-
ATTTCC-3, reverse: 5-TGCAGCGAACTTTATTGATG-
3). PCR reactions were performed for the number of cycles
indicated with denaturing at 94 °C and extension at 72 °C.
Quantitative Real-time PCR—Expression of the osteoblast-
specific markers alkaline phosphatase and osteocalcin and the
adipocyte marker peroxisome proliferator-activated recep-
tor- were analyzed by quantitative real-time PCR using the
TaqMan Universal PCR master mix (Applied Biosystems, Fos-
ter City, CA) and a sequence detection system (ABI Prism 7900
HT Sequence Detection System and Software, Applied Biosys-
tems) with fluorescence-labeled probes (reporter fluorescent
dye VIC at the 5-end and quencher fluorescent dye tetrameth-
ylrhodamine at the 3-end). The specific primers and probes
used are as follow for -actin (sense: 5-GGACCTGACGGA-
CTACCTCATG-3, antisense: 5-TCTTTGATGTCACGC-
ACGATTT-3, probe: 5-CCTGACCGAGCGTGGCTACA-
GCTTC-3), osteocalcin (sense: 5-GGAGGGCAATAAGG-
TAGTGAACA-3, antisense: 5-CACAAGCAGGGTTAA-
GCTCACA-3, probe: 5-CGGCGCTACCTTGGAGCCTC-
AGTC-3), and alkaline phosphatase (sense: 5-GGACTGGT-
ACTCGGATAACGAGAT-3, antisense: 5-ACATCAGTTC-
TGTTCTTCGGGTACA-3, probe: 5-CGCCACCCATGAT-
CACGTCGATATC-3). Primers and probes for peroxisome
proliferator-activated receptor-were analyzed using an inven-
toried kit from Applied Biosystems. To control variability in
amplification due to differences in starting mRNA concentra-
tions, -actin was used as an internal standard. The relative
expression of target mRNA was computed from the target Ct
values and the -actin Ct value using the standard curve
method (User Bulletin 2, Applied Biosystems).
In Situ Hybridization—Antisense and sense Riboprobes for
the mouse Y1 receptor were generated from a cDNA region
corresponding to bases 60–653 of the coding sequence (where
1 represents the first base of the translation initiation codon)
subcloned into pBluescript plasmid vector (Stratagene). Probes
were labeled with digoxigenin-UTP by in vitro transcription
with either T3 (antisense probe) or T7 (sense probe) RNA po-
lymerase using aDIGRNA labeling kit (RocheApplied Science)
according to the manufacturer’s instructions. Riboprobes were
purified from unincorporated label using Sephadex G-25 spin
columns, and their yield was assessed by dot blot.
In situ hybridization was carried out as previously described
with minor modifications (32) on 5-m sections of decalcified
bone. All procedures were carried out at room temperature
unless specified otherwise. Sections were dewaxed in xylene,
rehydrated through decreasing concentrations of ethanol
(100% to 70%), and then fixed in 2% paraformaldehyde in PBS
on ice for 10 min. After washing in PBS, sections were incu-
bated at 37 °C with proteinase K (Roche Applied Science) at a
concentration of 5g/ml in 50mMTris-HCl (pH 7.5) and 5mM
EDTA for 20 min, followed by 0.1 M glycine in PBS for 5 min.
Sections were acetylated with 1 triethanolamine containing
0.25% (v/v) acetic anhydride for 10 min and washed in PBS
before hybridization.
Hybridization was carried out overnight at 45 °C in a humid
environment. Sections were incubated with hybridization solu-
tion containing 50% formamide, 5 SSC, 250 g/ml salmon
sperm DNA, 250 g/ml yeast tRNA, 1 Denhardt’s solution,
10% dextran sulfate, 10 mM dithiothreitol, and 200 ng/ml
digoxigenin-labeled Riboprobe. The sections were washed in
2 SSC for 5min followed by 0.2 SSC at 62 °C for 30min and
0.1 SSC at 65 °C for 30min. Theywere then incubatedwith 20
g/ml RNase A (Roche Applied Science) in 0.5 M NaCl, 10 mM
Tris-HCl, and 1 mM EDTA at 37 °C for 15 min followed by
washes with 2 SSC for 5 min, 0.1 SSC at 37 °C for 30 min.
Following the washes, antidigoxigenin Fab antibody fragments
conjugated with alkaline phosphatase (Roche Applied Science)
and nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phos-
phate stock solution (Roche Applied Science) containing 1 mM
levamisole were used for colorimetric detection following the
manufacturer’s instructions.
Isolation of Mesenchymal Stem and Osteoprogenitor Cells—
Femurs, tibias, and iliac crests from 8- to 15-week-old male
micewere dissected and thoroughly cleaned ofmuscle and con-
nective tissue, after which the outer surface of the bones was
scraped to remove the periosteal surface. Long bones and iliac
crests were crushed using amortar and pestle in washing buffer
(2% fetal bovine serum in PBS), then cut up finely in 3 mg/ml
Worthington collagenase type 1. Bone fragmentswere then col-
lagenase-digested for 45 min at 300 rpm at 37 °C. Following
digestion, large fragments were removed by filtration (70-m
nylon mesh cell strainer, BD Biosciences). Cells were collected
by centrifugation (1000 rpm, 4min) and resuspended in 2ml of
washing buffer, and the viable cell number was counted using
trypan blue.
Contaminating hematopoietic cells were removed by lineage
depletion using magnetic activated cell sorting (MACS)
microbeads. Cells were incubated with a mixture consisting of
the purified antibodies against B220, Gr-1, Mac-1, CD4, CD8,
CD3, CD5 (all 1:500 dilution), and TER119 (1:1000 dilution)
(BD Pharmingen) diluted in washing buffer for 20 min at 4 °C.
Excess antibody was removed by centrifugation, and the cell
suspension was then incubated with MACS goat anti-rat IgG
magnetic microbeads (20 l per 107 cells, Miltenyi Biotech,
Bergisch-Gladbach, Germany) diluted in washing buffer for 15
min at 4 °C. The cell suspension containing the boundmagnetic
beads was then applied to a VarioMACS separator with an LS
MACS Cell Separation Column (Miltenyi Biotech). Eluted
negatively selected cells devoid of hematopoietic cells were col-
lected, centrifuged at 1200 rpm for 4 min, and resuspended in
500 l of washing buffer, and viable cells were counted using
trypan blue.
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To prepare for cell sorting for selection ofMSCs and progen-
itor cells, cells (3  106) were incubated for 20 min at 4 °C
with 2.5 l each of the biotinylated or fluorescein isothiocya-
nate- or phycoerythrin-conjugated antibodies against the sur-
face markers Sca-1, CD45 (BD Pharmingen), CD31, and CD51
(BD Biosciences). Appropriate controls (no antibody, isotype
control using nonspecific IgG, fluorescein isothiocyanate, phy-
coerythrin, biotinylated, and all antibodies) were also set up by
incubation of 0.5 l of antibody with 20,000 cells for each
control group. The secondary fluorescein allophycocyanin-
conjugated streptavidin (1:500 dilution, BD Biosciences) was
then added to all tubes containing the biotinylated-CD51 anti-
body (CD51 control tube, all antibodies, and experimental sam-
ples), incubated for a further 15 min at 4 °C. 7-Amino-actino-
mycin D (1:300 dilution, BD Biosciences) was used to detect
non-viable cells. Cells were then sorted using a FACS Vantage
SETM (BD Biosciences) with FACSDiva SETM software version
4.1.2 (BD Biosciences) using a nozzle size of 70 m at 4 °C to
remove remaining contaminating CD31 and CD45 hema-
topoietic cells. The remaining cell population now entirely
devoid of hematopoietic cell contamination was then sorted
based on Sca-1. Sca-1 MSC cells were collected. Sca-1
cells were further sorted based on the marker CD51, and
Sca-1CD51 cells were collected.
Culturing and Colony Formation of Sorted MSC and Progen-
itor Cells—Sca-1 and Sca-1CD51 cells from wild-type and
Y2/ mice were plated at a density of 1000 cells/well in 9.6-
cm2 plates (100 cells/cm2, BD Biosciences Labware) and cul-
tured in control media (see section above) containing 20% fetal
bovine serum, initially in 5%O2/10%CO2/85%N2 (Air Liquide,
Melbourne, Australia) at 37 °C for 3 days, then changed into
regular culture conditions at 37 °C and 5% CO2.
Formation of colonies by MSC and progenitor cells was
assessed by evaluation of CFUs on day 7 of culture, when indi-
vidual colonies were easily identifiable. Cells were initially fixed
with 4% formaldehyde, washed with PBS, then stained with fil-
tered (0.2-m filter, Sartorius, Hannover, Germany) 1% tolui-
dine blue for 15 min at room temperature. The number of pos-
itively stained colonies containing 5 cells was counted for
each experimental group.
Bone Densitometry—Bone mineral content (BMC) and bone
mineral density (BMD) were measured in excised individual
femora and tibia from 16-week-old Y1/ and wild-type mice,
following collection and fixation in 4% paraformaldehyde for
16 h using a dedicatedmouse dual x-ray absorptiometry (Lunar
Piximus II, GE Medical Systems, Madison, WI). Scanning was
performed with the knee joint in flexion to 90° to ensure con-
sistent placement and scanning of the sagittal profile.
Statistical Analysis—Statistical differences in extent of min-
eralization or adipocyte differentiation based on values
obtained from the image analysis software (Leica Microsys-
tems), and analyses of BMD and BMC in Y1/ mice, were
analyzed using two-tailed unpaired t tests between data from
the two genotypes at equivalent time points using StatView
version 4.5 (Abacus Concepts, San Francisco, CA). For all sta-
tistical analyses, p  0.05 was accepted as being statistically
significant.
RESULTS
Greater Mineralization and Adipocyte Formation in Cul-
tured Stromal Cells from Germ Line Y2/Mice—To examine
whether bone cells from germ line Y2/ mice exhibit differ-
ences in proliferation and mineralization in vitro, we isolated
bonemarrow stromal cells fromwild-type and germ line Y2/
mice and cultured them under osteogenic and adipogenic con-
ditions to induce differentiation down the osteogenic and adi-
pogenic lineages, respectively. Comparable numbers of cells
were isolated from flushed bone marrow from wild-type and
Y2/ mice (wild type, between 7.5  107 and 1.7  108 cells
versus Y2/, between 8 and 9.8 107 cells obtained from four
bones per mouse) and were then plated at equal density. Viable
cell numbers as assessed by trypan blue staining did not differ
significantly between mutant and wild-type cultures in non-
differentiating control conditions over a week in culture (data
not shown), suggesting stromal cells from the two genotypes
did not differ in their rate of proliferation.
A time-dependent increase in the extent of mineralization
was revealed in von Kossa-stained osteogenic cultures, with a
more marked accumulation of mineral in cultures from Y2/
mice compared with wild-type (Fig. 1A). These observations
were confirmed by measurements of total mineral area by
image analysis, with significantly greater mineralization meas-
ured in Y2/ cultures at days 18 and 21 (Fig. 1B). The pattern
ofmineralization also appeared to bemore evenly distributed in
the Y2/ cultures compared with wild-type cultures, in which
mineral appeared to be more centrally localized (Fig. 1A), sug-
gesting the presence of more mineral-producing osteoblastic
cells throughout the Y2/ cultures. Increases in expression of
the osteoblast marker genes alkaline phosphatase and osteocal-
cin at days 3 and 9 in Y2/ cultures supported these observa-
tions (Fig. 1C). Interestingly, under control culture conditions
with nodifferentiation-inducing supplements in themedia, von
Kossa-positivemineral was observed in somewells from Y2/
but not wild-type mice (data not shown). These findings
together suggest an increased capacity of osteoblastic cells
from Y2/ mice to produce mineralized extracellular
matrix in vitro.
Cells cultured under adipogenic conditions also showed ele-
vated expression of peroxisome proliferator-activated recep-
tor, a key regulator of adipocyte differentiation, in day 3 and
day 9 Y2/ cultures (Fig. 1C), as well as a time-dependent
increase in adipocyte differentiation, evidenced by Oil Red O
staining, with a significantly greater number of adipocytes on
days 18 and 21 of culture in cells from Y2/ compared with
wild-typemice (Fig. 1,D and E). Thus, cultures of bonemarrow
cells from Y2/ mice exhibited an enhanced capability to
undergo both osteoblast and adipocyte differentiation under
appropriate cell culture conditions.
Because proliferation rates of cultures from the two geno-
types were not different, the increased osteoblast mineraliza-
tion and adipocyte number in cultures from Y2/mice could
be the result of intrinsic differences in the ability of progenitor
cells to undergo osteoblast or adipocyte differentiation. Alter-
natively, because osteoblasts and adipocytes are derived from a
common mesenchymal precursor, the differences observed in
Greater Osteoprogenitor Number of Y2 KnockoutMice
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differentiation capability may result from a difference in the
number of the common mesenchymal progenitors present
within the bone of Y2/mice.
Increased Numbers of Osteoprogenitor Precursors in Germ
Line Y2/Mice—Using FACS, two mesenchymal progenitor
populations were isolated from wild-type and Y2/ mouse
bones to investigate the proportion at which these cells were
present in these genotypes. Previous studies have demonstrated
that only a small percentage of the total number of mesenchy-
mal progenitors are present within the bone marrow, with the
majority of mouse mesenchymal cells present within compact
bone (25); consequently, MSCs and
progenitor cells for these studies
were isolated from compact bone
tissue.
Consistent with the above results
with flushed bone marrow, compa-
rable numbers of cells were also pre-
pared from compact bone of wild-
type and Y2/ mice following
collagenase digestion (wild-type,
4.9 0.38 107 cells versus Y2/,
5.1 0.38 107 cells total from 10
mice, average cell numbers from
three separate experiments). Im-
portantly, although cell numbers
decreased markedly following
depletion of hematopoietic cells, the
cell yields remained similar between
the two genotypes (wild-type, 3.4
0.38 106 cells versus Y2/, 3.5
0.38  106 cells total from 10 mice,
average yield in three experiments).
After further negative selection of
CD45 and CD31 hematopoietic
cells, the population was sorted
based on the stemcell antigen Sca-1.
Sca-1 cells were gated and col-
lected, whereas Sca-1 cells were
sorted again and a Sca-1CD51
cell population was gated and col-
lected. Previous studies have estab-
lished that Sca-1 cells are imma-
ture mesenchymal stem cells (25,
28, 33), whereas Sca-1CD51 cells
represent amorematuremesenchy-
mal progenitor cell type.5
Numbers of Sca-1 MSCs were
comparable between wild-type and
Y2/ mice, but there was a 2-fold
greater number of Sca-1CD51
progenitor cells in bones from
Y2/ compared with wild-type
mice (Fig. 2). These findings suggest
that the greater mineralization and
adipocyte formation observed in the
initial bone marrow stromal cell
cultures from Y2/mice was likely
due to a greater proportion of maturemesenchymal progenitor
cells present at the initial plating.
Gene array analysis of the different subpopulations of Sca-1
cells confirmed the up/down-regulation of bone-specific genes
further supporting a role of these cells in increased bone forma-
tion (supplemental Table S1).
The CFU assay is an indication of the relative abundance of
proliferating progenitor cells within an isolated population
5 P. Simmons, unpublished data.
FIGURE 1. Stromal cells from Y2/mice exhibit greatermineralization and adipocyte differentiation in
vitro. A, von Kossa staining ofmineral in stromal cell cultures fromwild-type and Y2/mice. B, quantification
of mineral illustrates increased mineralization in Y2/ stromal cells cultured in osteogenic differentiation
media. C, the graphs show -fold difference of the bone and adipocyte marker genes alkaline phosphatase,
osteocalcin, and peroxisome proliferator-activated receptor; greater expression of these genes in cultured
stromal cells fromY2/mice relative towild-type (dotted lines) at days 3 and9of culture.D, adipocyte number
was increased inY2/ stromal cells cultured in adipogenicmedia. E, Oil RedOstainingof cultured stromal cells
shows greater adipocyte number in Y2/ cultures. *, p 0.05; **, p 0.01.
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available for differentiation down the
distinct mesenchymal lin-eages. Cells
within the colonies from Sca-1 and
Sca-1CD51 cellsweremorpholog-
ically different, with amore fibroblas-
tic appearance in the Sca-1 cells and
a more cuboidal morphology in Sca-
1CD51 cultures, consistent with
the proposed role of the latter popu-
lation as a more mature osteopro-
genitor cell type (Fig. 3A). Further-
more, CFU number was significantly
greater in Sca-1 comparedwithSca-
1CD51 cultures (p  0.001), con-
sistent with their proposed role as a
more immature cell type. Impor-
tantly, however, there was no differ-
ence in CFU number or notable dif-
ference in the size of the individual
colonies generated by either sorted
cell type from wild-type and Y2/
mice (Fig. 3,B andC), suggesting that
the abundance of progenitor cells
within these populations was compa-
rable between genotypes.
Y Receptor Expression in Bone
Marrow Stromal Cells—To explore
the molecular mechanism by which
progenitor cell number might be
increased in bones from Y2/
mice, the mRNA expression of dif-
ferentY receptor transcripts in bone
marrow stromal cell cultures from
wt and Y2/mice on day 3 and day
9 of culture was investigated.
Expression of all Y receptor tran-
scripts was detected in RNA iso-
lated from brain tissue of wild-type
mice using reverse transcription-
PCR (Fig. 4A, and data not shown),
confirming the ability of our prim-
ers to detect expression of the dif-
ferent Y receptor subtypes. Expres-
sion of Y1 mRNA was abolished in
brains of Y1/ knock-out mice
(Fig. 4A). Y1 receptor expression
was also demonstrated in bonemar-
row stromal cell cultures fromwild-
type mice but was all but abolished
in cultures from Y2/mice (Fig. 4,
B and C). This pattern was consis-
tently observed in control, osteo-
genic, and adipogenic culture con-
ditions. Expression of Y2, Y4, Y5,
and y6 receptors was not detected in
stromal cells from either genotype
at these time points (supplemental
Fig. S1 and data not shown).
FIGURE 2.Greater number ofmaturemesenchymal progenitor cells present in boneofY2/mice. The -fold
difference of Sca-1 MSCs and Sca-1CD51 mature progenitor cells in Y2/ bone compared with wild-type
(dotted line), average of three experiments (A), and proportion (B) of sorted populations in bones of wild-type and
Y2/mice (representative values fromoneof three experiments), shows a significant 2-fold increase in number of
Sca-1CD51 progenitor cells in Y2/ bones (p 0.05) but no difference in the number of Sca-1MSCs.
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Y1 Receptor Expression in Bone—Y1 receptor expression was
also investigated in bone tissue using in situ hybridization. Y1
receptor gene transcripts were detected in osteoblasts on
endocortical and trabecular bone surfaces within the distal
metaphysis of femurs from wild-type but not Y1/mice (Fig.
5,A–D). Y1 receptor expression was also detected in osteoblas-
tic cells of bones from Y2/ mice but appeared significantly
down-regulated relative to expression in wild-typemice (Fig. 5,
E and F). These findings together with the above data provide
clear evidence for the expression of Y1 receptors by osteoblastic
cells within bone tissue and ex vivo.
Greater Bone Density in Y1/ Mice—The presence of Y1
receptors on osteoblasts within bone tissue and their down-
regulation following Y2 receptor deletion suggest a key role for
local Y1 receptor signaling in the control of bone formation. To
FIGURE 3.MSC andmature progenitor cells fromwild-type and Y2/mice
are similar in their proliferative ability as assessedbynumbersofCFUs.Dif-
ference inappearanceofCFUsevidentafter toluidinebluestainingat100mag-
nification (A); CFU number after plating at equal density demonstrates no differ-
ence inCFUnumberbetweengenotypes (B); overviewof toluidineblue staining (C).
FIGURE 4.Y1 receptor is expressed in culturedbonemarrow stromal cells
from wild-type mice. Y1 receptor mRNA is detected in brain tissue of wild-
type but not Y1/mice (A). Y1 receptor is expressed in stromal cell cultures
fromwild-typemice at day 3 and 9 of culture under control, osteoblastic (OB),
and adipocytic (AD) conditions (B), and is down-regulated at both these time
points in stromal cells fromY2/mice (C). Numberof PCR cycles andproduct
size are indicated. Data show results for PCR performedwith () andwithout
() reverse transcription.
FIGURE 5. Y1 receptor expression in bone tissue. Analysis of Y1 receptor
expression by in situhybridization inwild-type, Y1/, and Y2/mice.A, B, E,
and F, 20magnification; C andD, 40magnification. Sense probe negative
control inwild-type and Y1/mice shows no staining (A). Antisense staining
of osteoblasts in trabecular and cortical bone of wild-type mice is absent in
Y1/mice (B–D). Y1 receptor expression is also associated with osteoblasts
in bones fromY2/mice (E), but senseprobe-negative control inY2/mice
again shows no staining (F). Arrows indicate Y1 receptor-positive osteoblasts.
Bar, 50 m (A, B, E, and F) and 12.5 m (C and D).
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investigate the effect of altered Y1 receptor signaling on bone
mass in vivo, femora and tibia from germ line Y1/mice were
assessed for changes in BMC and BMD. Consistent with an
inhibitory role of Y1 signaling on bone formation, femoral
BMD was significantly greater in Y1/ mice compared with
wild type, with a similar trend in femoral BMC (Fig. 6A). Simi-
larly, in the tibiae, both BMC and BMD were significantly ele-
vated in Y1/ mice compared with wild type (Fig. 6B), dem-
onstrating the ability of altered Y1 receptor signaling to alter
bone formation.
DISCUSSION
The findings presented here demonstrate that adherent bone
marrow stromal cells from Y2/mice have an enhanced abil-
ity to differentiate down osteoblastic and adipocytic lineages
compared with wild-type stromal cells in vitro. Analysis of the
population of mesenchymal progenitors within the bones of
these mice revealed a 2-fold greater number of mesenchymal
progenitor cells in Y2/ compared with wild-type mice. After
plating the immature Sca-1MSCs and the more mature Sca-
1CD51 cells from the wild-type and Y2/mice at the same
density, however, the number and sizes of colonies formedwere
similar between the two genotypes, indicating that these cells of
the two mouse genotypes were comparable in their colony-
forming ability and, therefore, most likely also in their differen-
tiation potential. Together these findings suggest that a change
in the size of a multipotential mesenchymal progenitor popu-
lation may be a contributing mechanism for the greater bone
mass of Y2/mice.
The greater mineralization seen in Y2/ stromal cell cul-
tures in vitro is consistent with the greater bone formation and
bone volume of the Y2/ model in vivo. In contrast, the
enhanced adipocytic differentiation capacity was initially sur-
prising, because the Y2/ mice have a lean phenotype, with
reduced white adipose mass compared with wild-type animals
(34) and a trend for reduced numbers of marrow adipocytes
(wild-type, 5.5  1.0 versus Y2/, 2.3  1.2 adipocytes per
distal femur 5-m sagittal section, p 	 0.09). However, the
greater number of mature multipotential progenitors in Y2/
bones is consistent with an enhanced ability of cultured stromal
cells from Y2/ mice to differentiate down either the osteo-
blastic or the adipocytic lineage under appropriate culture con-
ditions. Thus, unlike the consistent positive effects of Y2 recep-
tor gene deletion on the osteogenic cell lineage in vitro and in
vivo, the greater adipocytic differentiation in Y2/ cells
observed in vitro does not necessarily reflect the in vivo
situation.
To date, there is no standard method for the isolation of
murine mesenchymal stem or progenitor cells. Different
approaches have yielded populations of cells with variability in
their proliferative and differentiative capacities (24, 26–28, 33,
35–37). In the present study, a purified hematopoietic-depleted
cell population was further divided into immature MSC and
mature progenitor cells based on the presence or absence of
Sca-1. Sca-1 is a cell surface glycoprotein commonly used as a
marker for the isolation of hematopoietic stem cells from
mouse bone marrow. Although the physiological role of Sca-1
in the hematopoietic lineage is incompletely understood, its
presence appears to be required for normal hematopoietic stem
cell activity and lineage fate, and possibly also for the appropri-
ate self-renewal and homing ability of hematopoietic stem cells
(38, 39). Importantly, however, Sca-1 is also expressed on non-
hematopoietic bone marrow stromal cells, and mice lacking
Sca-1 develop late-onset osteoporosis due to a deficiency in
osteoprogenitor cells (40). Therefore, Sca-1 expression also
appears to be required for the appropriate self-renewal of mes-
enchymal progenitors and identifies a population of immature
mesenchymal cells with the ability to undergo osteoblast differ-
entiation. The Sca-1 cell population isolated from bone fol-
lowing depletion of hematopoietic cells, which represent an
immature multipotential cell type, did not differ between
Y2/mice and wild-type mice. The number of Sca-1CD51
mature progenitor cells, however, was 2-fold greater in bones
from Y2/ mice relative to wild type. The greater number of
these more mature progenitor cells provides a likely mecha-
nism by whichmineralization and adipogenesis were increased
in stromal cell cultures from Y2/mice compared with wild-
type. These findings support the likelihood that an increase in
the progenitor population may contribute to the increased
bone formation and volume of Y2/mice in vivo.
Previous studies have demonstrated the presence of NPY-
immunoreactive fibers in periosteum and bone marrow and
associated with bone lining cells in vivo (3, 41). Also, adminis-
tration of NPY inhibited the cAMP response to parathyroid
hormone and norepinephrine in some osteoblastic cell lines in
vitro (4, 42), suggesting the presence of functional NPY recep-
tors on bone cells and a possible role for NPY in the regulation
FIGURE 6.Greater bonemineral content and density in Y1/mice. Anal-
ysis of BMC and BMD in the femora (A) and tibiae (B) of wild-type and Y1/
mice, reveals greater femoral BMD and tibial BMC and BMD in Y1/ mice
comparedwithwild-type. *, p 0.05; **, p 0.01. Number of bones analyzed
per group, 8–10.
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of osteoblast activity. Our evaluation of the expression of the
different Y receptors in cultures of bone marrow stromal cells
from wild-type and Y2/mice under different differentiation
conditions revealed high levels of Y1 receptor expression in
wild-type cultures under normal, osteogenic, and adipogenic
conditions. Furthermore, expression of Y1 receptor in osteo-
blasts on endocortical and trabecular bone surfaces within
femur bone tissuewas detected using in situ hybridization, pro-
viding supporting evidence for the presence of Y1 receptors on
bone forming cells.
The observation that Y1 receptor expression was virtually
abolished in cultures from Y2/ mice suggests that reduced
Y1 receptor signaling in the bone microenvironment is impor-
tant for the anabolic bone phenotype of the Y2/ model.
Importantly, these studies also revealed that germ line deletion
of Y1 receptors resulted in greater BMD and BMC in vivo. Fur-
ther characterization of this model has demonstrated the
greater bone volume of the Y1/ model to be the result of a
greater rate of bone formation, which, unlike the Y2/model,
does not appear to be regulated via a central mechanism (see
accompanying report (46)). The direct linkage of hypothalamic
to peripheral changes in osteoblast activity has also been
described in leptin-deficient ob/obmice. In that model central
leptin signaling within the hypothalamus has a direct neural
connection to osteoblasts via sympathetic neurons, which alter
osteoblast activity by modulation of 2 adrenergic receptors
expressed on these cells (19). In a similar manner, central Y2
signaling may regulate osteoblast activity by NPY-ergic neuro-
nal modulation of osteoblastic Y1 receptors. Although these
two pathways appear to have separate mechanisms, interaction
between the Y2 and leptin pathways is still an open question.
Interestingly, consistent with this possibility, Y2//ob double
knock-outmice do not show additive effects on bone formation
(43). It is plausible that deletion of Y2 receptors either directly
or indirectly leads to a change in Y1 receptormRNA expression
in bone, with downstream consequences on osteoblast activity.
Altered expression of remaining Y receptors within certain
brain regions has been observed in germ line Y receptor knock-
out models, indicative of cross-regulation between different Y
receptors or overlapping functions in different signaling path-
ways (44). In the Y2/ model, it is likely that the lack of Y2
receptor signaling mediates the down-regulation of Y1 recep-
tors in osteoblast precursors, because the evidence from the
present study indicates a lack of Y2 receptor mRNA in bone
cells. Y2 receptors are known to be expressed on the pre-syn-
aptic side of sympathetic nerve terminals and act in an autoin-
hibitory fashion to regulate the release of NPY and other neu-
rotransmitters (45). The lack of this feedback inhibition onNPY
release could lead to elevated levels ofNPY,which in turnmight
then cause an overstimulation of Y1 receptors on bone precur-
sor cells, and subsequently to desensitization and down-regu-
lation of this Y1 receptor population. This would also be con-
sistent with the increased bone formation observed after
hypothalamus-specific Y2 receptor deletion, whereby sympa-
thetic nervous activity is potentially altered, thereby leading to
increased transmitter release (including NPY) in the periphery
and causing a similar down-regulation of Y1-receptors on bone
forming cells. This is supported by a recent study, which used
pseudorabies virus-based transneuronal tracing to map trans-
synaptically connected neurons from rat bone providing direct
evidence that nerve fibers within bone tissue are under the con-
trol of synaptic transmission from the hypothalamus (5). How-
ever, it cannot be excluded that part of the effect onY1-receptor
down-regulation is due to NPY produced by cells such as
megakaryocytes within the bone marrow itself (6).
In summary, we have shown here that the NPY system plays
an important part in the differentiation and proliferation of
osteoblastic and adipocytic lineages, with a greater number of
mesenchymal progenitor cells present in bones from Y2/
mice. The likely mechanism leading to greater bone formation
in Y2/ mice appears to be due to increased NPY levels and
subsequent down-regulation of Y1 receptors on bone cells. Ini-
tial studies presented in this report suggest a key role for local
Y1 receptor signaling in the control of osteoblast activity. These
findings together identify potential new avenues for the treat-
ment and prevention of bone loss. For a much more detailed
characterization of the role of Y1 receptors and their interac-
tion with Y2 receptors in the control of bone formation, the
reader is referred to the accompanying report (46).
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Methods - Supplementary figures and tables
Supplementary table 1: Transcriptome profile analysis.
Total cellular RNA was prepared from 10x103 freshly isolated cells of each cell
population obtained from 10 mice of each genotype, using RNeasy mini Columns
(Qiagen) according to manufacturer’s instructions. RNA was then amplified and labeled
using the Two-cycle Target Labeling and Control Reagents (Affymetrix, Santa Clara CA)
according to the manufacturer’s instructions. 15µg of biotinylated amplified cRNA were
hybridized onto Affymetrix GeneChip arrays MOE430 Plus-2.0 (Affymetrix). Arrays
were scanned using Gene Array Scanner (Affymetrix). Affymetrix GCOS 0.0 was used
for data acquisition and analysis. The comparative analysis of results obtained for the
different cell population was performed using the Silicon Genetics GeneSpring GX 7.3.1
software (Agilent Technologies, Palo Alto CA), using combined data from two separate
arrays with each array incorporating pooled cells from 10 animals. Affymetrix CEL files
were normalized using the GC-RMA method. List of genes differentially expressed by at
least two fold between cells isolated from wild type mice and from Y2-/- mice were
generated. The enrichment of the gene list with genes from a particular Gene Ontology
(GO) category was calculated using the Gene Ontology Browser and sorted by p-value.
GO categories with p-values >0.01 and containing 3 or less genes from the list were
discarded.
Supplementary figure 1: RNA extraction and Reverse Transcriptase-Polymerase
Chain Reaction (RT-PCR) analysis of cultured bone marrow stromal cells.
RNA was isolated from cultures of BMSCs in 12-well plates using Trizol Reagent and
RT-PCR was performed as described in Experimental Procedures in the manuscript. The
specific primers for amplification of mY1 and mY2 receptor mRNA and annealing
temperatures used along with the resultant product size obtained were: mY1 receptor
(323bp, 55°C) forward: 5' CTCGCTGGTTCTCATCGCTGTGGAACGG-3', reverse: 5'-
GCGAATGTATATCTTGAAGTAG-3', mY2 receptor (520bp, 60°C) forward: 5'-
TCCTGGATTCCTCATCTGAG-3', reverse: 5'-GGTCCAGAGCAATGACTGTC-3'.
PCR reactions were performed for the number of cycles indicated with denaturing at
94°C and extension at 72°C.
Figure legends – Supplementary tables and figures
Supplementary table 1
Lists of genes differentially expressed by at least 2-fold in sorted Sca+ and Sca-CD51+
cell populations isolated from Y2-/- and wild type mice, with potential to affect osteoblast
or adipocyte differentiation. The transcriptome of the freshly isolated mesenchymal cells
from the compact bone from the Y2-/- and the wild type mice was performed using the
Affymetrix platform, and the statistically significant gene ontology (GO) categories
associated with each list was retrieved. No statistically significant difference was
observed in GO categories related to bone metabolism.
Supplementary figure 1
mRNA for the Y2 receptor is not detectable in cultured bone marrow stromal cells
isolated from wild type mice. However, Y1, but not Y2 receptor mRNA is expressed in
stromal cell cultures from wild type mice at day 3 and to a lesser extend at day 9 of
culture under control conditions. Neither Y1 nor Y2 receptor mRNA was detectable in
stromal cell cultures from Y2-/- mice. Number of PCR cycles and product size are
indicated on figure. Data shows results for PCR performed with (+) and without (-)
reverse transcription.
2-fold enriched in Sca-CD51+ Y2-/- cells relative to wild type
fold change gene
17.4 & 21.1 leptin receptor
14.5 lipase, hepatic
14.5 estrogen receptor 1 (alpha)
13.8 adipocyte complement related protein (adipoq/adiponectin)
12.3 BMP-binding endothelial regulator
10.3 procollagen, type XIV, alpha 1
8.5 lipoprotein lipase
5.7 insulin-like growth factor binding protein 4
5.4 interleukin 6
4.7 insulin-like growth factor binding protein 4
4.5 CCAAT/enhancer binding protein (C/EBP), alpha
4.5 dentin matrix protein 1
4.3 apolipoprotein E
4.1 catenin beta
3.3 bone gamma carboxyglutamate protein 1
2.4 procollagen, type IX, alpha 1
2.2 procollagen, type IX, alpha 2
2.2 insulin-like growth factor binding protein 3
2.1 fibroblast growth factor receptor 1
2-fold enriched in Sca-CD51+ wild type cells relative to Y2-/-
3.3 Kruppel-like factor 5
2.5 procollagen, type XIII, alpha 1
2.4 matrix metalloproteinase 9
2-fold enriched in Sca+ Y2-/- cells relative to wild type
3.3 procollagen, type IX, alpha 1
3.2 osteoclast stimulating factor 1
3 dishevelled 2, dsh homolog (Drosophila)
2.8 tumor necrosis factor (ligand) superfamily, member 6
2-fold enriched in Sca+ wild type cells relative to Y2-/-
10.4 matrix metalloproteinase 13
5.8 bone morphogenetic protein 6
5.5 adipose differentiation related protein
5.5 estrogen receptor 1 (alpha)
4 catenin beta
3.7 very low density lipoprotein receptor
3.6 parathyroid hormone receptor 1
3.3 interferon gamma receptor
3.1 bone gamma carboxyglutamate protein 1
2.8 dickkopf homolog 3 (Xenopus laevis)
2.8 leptin receptor
2.7 very low density lipoprotein receptor
2.7 dickkopf homolog 2 (Xenopus laevis)
2.6 bone morphogenetic protein 1
2.6 lipoprotein lipase
2.5 osteomodulin
2.4 CCAAT/enhancer binding protein (C/EBP), alpha
2.3 colony stimulating factor 1 (macrophage)
2.1 collagen, type XXIV, alpha 1
2.1 insulin-like growth factor binding protein 4
2 fibroblast growth factor receptor 1
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36
GAPDH  269bp
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Y2  520bp 38
 Y2-/- mice
  Day 3     Day 9
 +     -      +     -
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